Atyr Pharma Inc. (LIFE) PT Set at $8.00 by BMO Capital Markets
Atyr Pharma Inc. (NASDAQ:LIFE) has been assigned a $8.00 price objective by investment analysts at BMO Capital Markets in a research note issued on Thursday. The brokerage currently has a a “hold” rating on the stock. BMO Capital Markets’ price objective would indicate a potential upside of 175.86% from the company’s current price.
Several other equities research analysts have also recently issued reports on the stock. Citigroup Inc. raised their price objective on shares of Atyr Pharma from $3.00 to $4.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 16th. JPMorgan Chase & Co. cut their price objective on shares of Atyr Pharma from $15.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, August 11th. Finally, Zacks Investment Research upgraded shares of Atyr Pharma from a “hold” rating to a “buy” rating and set a $4.00 price objective for the company in a research report on Tuesday, August 16th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $6.50.
Shares of Atyr Pharma (NASDAQ:LIFE) traded down 2.36% during midday trading on Thursday, hitting $2.90. 135,403 shares of the stock traded hands. Atyr Pharma has a 52-week low of $2.48 and a 52-week high of $13.26. The stock has a 50-day moving average of $3.15 and a 200-day moving average of $3.30. The company’s market cap is $68.78 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/07/atyr-pharma-inc-life-pt-set-at-8-00-by-bmo-capital-markets.html
Atyr Pharma (NASDAQ:LIFE) last released its quarterly earnings data on Wednesday, August 10th. The company reported ($0.65) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.06. On average, equities analysts predict that Atyr Pharma will post ($2.56) earnings per share for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in the company. BlackRock Institutional Trust Company N.A. boosted its stake in Atyr Pharma by 317.4% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 344,214 shares of the company’s stock valued at $957,000 after buying an additional 261,753 shares during the last quarter. BlackRock Advisors LLC boosted its stake in shares of Atyr Pharma by 14,820.9% in the second quarter. BlackRock Advisors LLC now owns 244,405 shares of the company’s stock worth $679,000 after buying an additional 242,767 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Atyr Pharma by 120.3% in the second quarter. Vanguard Group Inc. now owns 439,732 shares of the company’s stock worth $1,223,000 after buying an additional 240,101 shares in the last quarter. Emerald Acquisition Ltd. bought a new stake in shares of Atyr Pharma during the second quarter worth $206,000. Finally, Jackson Park Capital LLC bought a new stake in shares of Atyr Pharma during the second quarter worth $183,000. Hedge funds and other institutional investors own 44.75% of the company’s stock.
About Atyr Pharma
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for Atyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.